Status:
COMPLETED
Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States
Lead Sponsor:
Novartis
Conditions:
Parkinson's Disease
Eligibility:
All Genders
30+ years
Phase:
PHASE4
Brief Summary
This study examines the effect of treatment of levodopa/entacapone on quality of life, as measured by the Parkinson's Disease-Questionnaire 8 (PDQ-8), in Parkinson's disease patients with no or minima...
Detailed Description
This study examines the effect of treatment of levodopa/entacapone on quality of life, as measured by the Parkinson's Disease-Questionnaire 8 (PDQ-8), in Parkinson's disease patients with no or minima...
Eligibility Criteria
Inclusion
- Clinical diagnosis of idiopathic Parkinson's disease exhibiting at least 2 or 3 symptoms
- Motor functions must be regarded as non-disabling by the patient
Exclusion
- History, signs or symptoms suggesting the diagnosis of atypical or secondary parkinsonism
- History of dyskinesia
- Previous or current use of entacapone or tolcapone
- Unstable Parkinson's disease patients requiring/receiving regimens of levodopa
- Subjects taking levodopa/DDCI controlled release or extended release formulations
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT00143026
Start Date
July 1 2005
End Date
June 1 2006
Last Update
March 29 2017
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Adelaide Hospital
Adelaide, Australia
2
Watkins Medical Center
Brisbane, Australia
3
Central Coast Neuroscience Research
Gosford, Australia
4
Heidelberg Repatriation Hospital
Melbourne, Australia